ES
ESLA
—
Nasdaq
Biotechnology & Medical Research
Estrella Immunopharma, Inc.
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
29,5M USD
P/E
—
EV / Rev
—
Div yield
—
Op margin
—
ROE
43,5 %
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
$0,91
Open
—
Next earnings
2026-08-09
Ex-dividend
—
TR 1Y
—
About
Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company developing T-cell therapies for blood cancers and solid tumors, relying on external financing and strategic services agreements to fund operations.
Business. Estrella Immunopharma, Inc. (ESLA) is a pharmaceutical company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership→
Wells Fargo Advisors
largest disclosed fund holder
Profitability→
43,5 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to ESLA. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-08-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
Estrella Immunopharma, Inc. (ESLA) is a pharmaceutical company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
AI synthesis
GENERATEDEstrella Immunopharma presents a distressed capital structure characterized by negative total equity of $-5.27 million and total liabilities of $8.93 million against total assets of $3.66 million. The current ratio stands at 0.24, indicating that current liabilities significantly exceed current assets, while cash and equivalents total $1.38 million. Operating cash flow for the quarter was negative $6.70 million, reflecting substantial cash burn from operations. The company mitigated immediate liquidity pressure through financing activities, receiving approximately $8.00 million from the issuance of common stock, prefunded warrants, and common stock warrants in a registered direct offering.
Profitability metrics are negative, with a net loss of $2.29 million and an operating income of the same amount for the quarter. Return on assets is -0.63, and return on equity is reported as 0.43, though this ROE figure is distorted by the negative equity base. The company has no revenue generation, typical for a pre-commercial clinical-stage biopharma, resulting in an EV/EBITDA of -20.53. The fundamental economics rely entirely on capital preservation and successful clinical advancement rather than operational profitability.
Key takeaways
- Negative equity of $-5.27 million and a current ratio of 0.24 signal severe balance sheet distress and high liquidity risk.
- Recent registered direct offering raised ~$8.00 million but increased basic shares from 36.68m to 43.18m, confirming high dilution pressure.
- Operating cash burn accelerated to $6.70 million in Q1 2026, up from $0.47 million in Q1 2025, driven by accrued liabilities.
- Stock price dropped below $1.00 ($0.91), triggering Nasdaq continued-listing deficiency warnings.
- Material weaknesses in internal controls and going-concern doubts persist due to lack of qualified accounting personnel and recurring losses.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Quarterly
Annual
QUARTERLYFiled 2026-03-31
Q4 2025 · Quarter highlights
Operating income -$2.3M.
Revenue—
Operating income-$2.3M
Net income-$2.3M
Free cash flow—
EPS—
Operating cash flow-$6.7M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$2.3M
Net income-$2.3M
Balance sheet
Total assets$3.7M
Total liabilities$8.9M
Total equity-$5.3M
Cash & equivalents—
Long-term debt—
Cash flow
Operating cash flow-$6.7M
CapEx—
Free cash flow—
SBC$146.7k
Highlights
- ▍Operating income -$2.3M
QUARTERLYFiled 2025-09-30
Q2 2025 · Quarter highlights
Operating income -$12.4M.
Revenue—
Operating income-$12.4M
Net income-$12.5M
Free cash flow—
EPS—
Operating cash flow-$1.6M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$12.4M
Net income-$12.5M
Balance sheet
Total assets$3.5M
Total liabilities$13.4M
Total equity-$9.8M
Cash & equivalents$1.6M
Long-term debt—
Cash flow
Operating cash flow-$1.6M
CapEx—
Free cash flow—
SBC$470.6k
Highlights
- ▍Operating income -$12.4M
QUARTERLYFiled 2025-06-30
Q1 2025 · Quarter highlights
Operating income -$7.6M.
Revenue—
Operating income-$7.6M
Net income-$7.6M
Free cash flow—
EPS—
Operating cash flow-$880.9k
Financials
Income statement
Revenue—
Gross profit—
Operating income-$7.6M
Net income-$7.6M
Balance sheet
Total assets$3.0M
Total liabilities$9.1M
Total equity-$6.1M
Cash & equivalents$1.3M
Long-term debt—
Cash flow
Operating cash flow-$880.9k
CapEx—
Free cash flow—
SBC$318.2k
Highlights
- ▍Operating income -$7.6M
ANNUALFiled 2025-12-31
FY 2025 · Full-year highlights
Operating income -$13.1M.
Revenue—
Operating income-$13.1M
Net income-$13.1M
Free cash flow—
EPS—
Operating cash flow-$1.8M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$13.1M
Net income-$13.1M
Balance sheet
Total assets$3.2M
Total liabilities$13.5M
Total equity-$10.4M
Cash & equivalents$1.4M
Long-term debt—
Cash flow
Operating cash flow-$1.8M
CapEx—
Free cash flow—
SBC$619.0k
Highlights
- ▍Operating income -$13.1M
ANNUALFiled 2024-12-31
FY 2024 · Full-year highlights
Operating income -$4.4M.
Revenue—
Operating income-$4.4M
Net income-$4.4M
Free cash flow—
EPS—
Operating cash flow-$3.1M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$4.4M
Net income-$4.4M
Balance sheet
Total assets$3.1M
Total liabilities$3.0M
Total equity$143.7k
Cash & equivalents$916.9k
Long-term debt—
Cash flow
Operating cash flow-$3.1M
CapEx—
Free cash flow—
SBC$432.3k
Highlights
- ▍Operating income -$4.4M
ANNUALFiled 2024-12-31
FY 2025 · Full-year highlights
Operating income -$4.4M.
Revenue—
Operating income-$4.4M
Net income-$4.4M
Free cash flow—
EPS—
Operating cash flow-$3.1M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$4.4M
Net income-$4.4M
Balance sheet
Total assets$3.1M
Total liabilities$3.0M
Total equity$143.7k
Cash & equivalents$916.9k
Long-term debt—
Cash flow
Operating cash flow-$3.1M
CapEx—
Free cash flow—
SBC$432.3k
Highlights
- ▍Operating income -$4.4M
ANNUALFiled 2024-06-30
FY 2024 · Full-year highlights
Operating income -$7.3M.
Revenue—
Operating income-$7.3M
Net income-$7.3M
Free cash flow—
EPS—
Operating cash flow-$16.1M
Financials
Income statement
Revenue—
Gross profit—
Operating income-$7.3M
Net income-$7.3M
Balance sheet
Total assets$4.5M
Total liabilities$180.7k
Total equity$4.3M
Cash & equivalents$4.2M
Long-term debt—
Cash flow
Operating cash flow-$16.1M
CapEx—
Free cash flow—
SBC$1.2M
Highlights
- ▍Operating income -$7.3M
Valuation FY
Market price
$0,70
Market cap
$48.4M
Enterprise valueⓘ
$47.1M
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
-$5.3M
Net cashⓘ
$1.4M
Current ratioⓘ
0.2
Debt / equityⓘ
—
ROAⓘ
-62.7%
ROEⓘ
43.5%
Cash conversionⓘ
292.0%
CapEx / revenueⓘ
—
SBC / revenueⓘ
—
Dilution ratioⓘ
11.5%
Revenue by segment
Business relationships
Business relationships1 disclosed relationship · 1 type · extracted from filings & disclosures
Suppliers1
Eureka Group Holdings LtdEGH.AXSupplier95%
Supply chain
Vendors → ESLA ↔ Partners → Customers · click any node to drill
0 mentions in 10-K0 from corporate websites0 from news dispatches
Updated 2026-07-08Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,39
Predicted surprise
0,00
Beat probability
45 %
Analysts
—
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-16 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,39 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | -18,5M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageOperating income · consensus-18,5M USD
EPS surprise
+46,2 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
— missing data
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskHigh
Liquidity riskHigh
Filing-based flags
- Diluted share count is materially above the basic share count.
- Current liabilities exceed current assets.
- Filings reference going-concern or substantial-doubt language.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
ROE43,5 %Best in class
D/E-0,00Above median
Cash Conv2,92Best in class
Corporate actions / M&A
— missing data
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
— missing data
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
How metrics are computed
- Return On Assetsnet_income / total_assets
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Enterprise Valuemarket_cap - net_cash
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
Source documents
- Estrella Immunopharma, Inc. company facts · 2026-07-08
- Estrella Immunopharma, Inc. 10-Q 2026-05-18 · 2026-07-08
- Estrella Immunopharma, Inc. 10-K 2026-03-18 · 2026-07-08
- Estrella Immunopharma, Inc. 10-Q 2025-11-12 · 2026-07-08
- Estrella Immunopharma, Inc. 10-Q 2025-08-12 · 2026-07-08
- ha_price_listing fired on ESLA · 2026-07-08
- Estrella Immunopharma, Inc. HA canonical relationships · 2026-07-08
Ownership & reference
Top holders
- Brokerage Firms · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
Insider activity
Net buying3 buys · 0 sellsnet $3K1 insiders · last 365d
- Chief Financial Officer · Common Stock, par value $0.0001 per shareBought 1 000 @ $1,33$1K · 2025-10-07
- Chief Financial Officer · Common Stock, par value $0.0001 per shareBought 1 000 @ $1,16$1K · 2025-09-22
- Chief Financial Officer · Common Stock, par value $0.0001 per shareBought 100 @ $1,04$104 · 2025-09-11
Short positioning
54.5Kshares short-38.9% vs prior
1.19days to cover
29.8%short of daily vol
553fails-to-deliver
as of 2026-07-15 · short-interest report (free)
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
ESLACanonical
Nasdaq · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskHigh
Liquidity riskHigh
Diluted share count is materially above the basic share count.
Current liabilities exceed current assets.
Filings reference going-concern or substantial-doubt language.
Source documents mention dilution or offering risk.
Relationship graph
This companySectorSuppliers
Evidence & claims
From filings & derived data- R&D expense (YoY) (2025-12-31 vs 2024-06-30): 149.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-06-30): -78.7%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-06-30): 88.9%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-06-30): -29.6%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-06-30): -29.6%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 1.2%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -7,312.1%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 351.9%Derived (calculated)
- Return on equity (FY 2025-12-31): 126.0%Derived (calculated)
- Return on assets (FY 2025-12-31): -411.2%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.12xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): -1.31xDerived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-06-30): -78.7%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 51.0%Derived (calculated)
- Total operating expenses (annual): USD 13.06MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
- Pre-tax income (annual): USD -13.06MSEC XBRL filing
- Cash & equivalents (annual): USD 1.38MSEC XBRL filing
- Total liabilities (annual): USD 13.54MSEC XBRL filing
- Total assets (annual): USD 3.18MSEC XBRL filing
- Shareholders' equity (annual): USD -10.37MSEC XBRL filing
- Net income (annual): USD -13.06MSEC XBRL filing
- Operating cash flow (annual): USD -1.79MSEC XBRL filing
- Current assets (annual): USD 1.68MSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-08-09EVENTUpcomingFY 2026 earnings (expected) estimated date
2026-07-07 21:52 UTCEVENTHa Price Listing ESLA price below 1 ($0.91) — US continued-listing minimum-bid threshold
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-03-31EARNINGSQuarterly results — Q4 2025 Net USD -2.3M
2025-12-31EARNINGSQuarterly results — Q3 2025
2025-12-31EARNINGSAnnual results — FY 2025 Net USD -13.1M
2025-10-07 00:00 UTCINSIDER1 insider transaction — 2025-10
2025-10-07INSIDERXu Jiandong bought 1.0k sh Common Stock, par value $0.0001 per share — Chief Financial Officer ~$1k
2025-09-30EARNINGSQuarterly results — Q2 2025 Net USD -12.5M
2025-09-22 00:00 UTCINSIDER2 insider transactions — 2025-09
2025-09-22INSIDERXu Jiandong bought 1.0k sh Common Stock, par value $0.0001 per share — Chief Financial Officer ~$1k
2025-09-11INSIDERXu Jiandong bought 100 sh Common Stock, par value $0.0001 per share — Chief Financial Officer ~$0k
2025-06-30EARNINGSQuarterly results — Q1 2025 Net USD -7.6M
2024-12-31EARNINGSAnnual results — FY 2024 Net USD -4.4M
2024-10-30 00:00 UTCINSIDER4 insider transactions — 2024-10 4 derivative
2023-09-29 00:00 UTCINSIDER1 insider transaction — 2023-09 · net sell $2.8M
2022-03-04 00:00 UTCINSIDER1 insider transaction — 2022-03 · net buy $44.68B
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data
Premium coverage